Talazoparib (Talazoparib) role and efficacy

Talazoparib is a prescription drug used alone to treat adults with a certain type of breast cancer (human epidermal growth factor receptor 2 [HER2]-negative) who have an abnormal BRCA gene and whose cancer has spread to other parts of the body (locally advanced or metastatic). It is not known whether talazopanib is safe and effective in children.

Talazopanib is an inhibitor of PARP, an enzyme that helps repair DNA when it is damaged. Blocking PARP may help prevent cancer cells from repairing damaged DNA, causing them to die. PARP inhibitors are often targeted therapies, and treatment with talazopanib can effectively slow or stop tumor growth in patients with advanced cancer. Poly ADP ribose polymerase (PARP) repairs DNA damage in healthy cells and cancer cells. Research shows that drugs like talazopanib that interfere with (inhibit) the PARP enzyme make it harder for cancer cells with BRCA1 or BRCA2 mutations to repair DNA damage. This makes it harder for cancer cells to survive. In other words, PARP inhibitors reduce the likelihood that some cancer cells will survive DNA damage.

The original drug of talazopanib has not yet been marketed in China, so it has not been included in medical insurance. The original drug specification of talazopanib listed overseas is 0.25mg*30 capsules, and the price per box may be around RMB 10,000 (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheaper generics of talazopanib overseas. For example, the price of a box of 1mg*30 pills produced by a Laos pharmaceutical factory may be more than 3,000 yuan (the price may fluctuate due to the exchange rate).